All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III studyDavid R. Nelson, Eric Lawitz, Paul J. Pockros et al.|Hepatology|2015Cited by 689
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV InfectionMarc Bourlière, Stefan Zeuzem, Stuart C. Gordon et al.|New England Journal of Medicine|2017Cited by 565